Arcturus therapeutics announces second quarter 2024 financial update and pipeline progress

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global messenger rna medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare diseases, today announced its financial results for the second quarter ended june 30, 2024, and provided corporate updates. “we are pleased to remain on track for our first commercial product launch of kostaive® in japan lat.
ARCT Ratings Summary
ARCT Quant Ranking